Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.
On Tuesday, a US Senate Finance Committee hearing on drug pricing focused on addressing the role of pharmacy benefit managers (PBMs) in determining cost to patients.
Approximately 1 in 5 patients in a study were misdiagnosed with multiple sclerosis before being referred to treatment centers.
Top news of the day from across the health care landscape.
Amgen’s ABP 501 (Amjevita) shows similar efficacy to the reference adalimumab (Humira) in treating rheumatoid arthritis and supported approval of the biosimilar by the FDA.
With this approval, patients with HIV who have never been treated have the option of a 2-drug regimen in a single tablet.
Adenosine deaminase is an ultra-rare and inherited disorder that is detrimental to the immune system and causes severe combined immune deficiency.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.